Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Moussa, S; Ansari-Shahrezaei, S; Smretschnig, E; Hagen, S; Steindl-Kuscher, K; Krebs, I; Binder, S.
Contrast sensitivity after intravitreal antivascular endothelial growth factor therapy for myopic choroidal neovascularization.
Graefes Arch Clin Exp Ophthalmol. 2010; 248(8):1087-1090
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Ansari Shahrezaei Siamak
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
To evaluate contrast sensitivity (CS) using Pelli-Robson charts after intravitreal ranibizumab (IVR) (Lucentis, Novartis, Basel, Switzerland) or bevacizumab (IVB) (Avastin, Genentech, South San Francisco, California, USA) in eyes with myopic choroidal neovascularization (mCNV). A retrospective review was performed of 17 consecutive patients treated with IVR (n = 10; 0.5 mg) or IVB (n = 7; 1.25 mg) for mCNV from July, 2006 with follow-ups through September, 2009. Re-treatment was performed at monthly or longer intervals if there was fluorescein leakage in fluorescein angiogram (FAG) and or apparent subretinal fluid in optical coherence tomography (OCT) persisted. CS improved by a mean of one letter at 1 month (n = 17; p = 0.32), four letters at 3 months (n = 17; p = 0.02), four letters at 6 months (n = 15; p = 0.01), five letters at 9 months (n = 14; p = 0.04) and six letters at 12 months (n = 13; p = 0.03). The mean number of IVR/IVB was 1.6/1.6, 2.6/2.3, 3.1/3.2, 4.1/4.2 and 4.5/4.6 at 1 month, 3 months, 6 months, 9 months, and 12 months, respectively. Improvements in Pelli-Robson CS scores were observed during the first year after IVR/IVB in eyes with mCNV.
Find related publications in this database (using NLM MeSH Indexing)
Angiogenesis Inhibitors - administration & dosage
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized -
Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology
Contrast Sensitivity - physiology
Female -
Fluorescein Angiography -
Humans -
Injections -
Male -
Middle Aged -
Myopia, Degenerative - drug therapy Myopia, Degenerative - physiopathology
Retreatment -
Retrospective Studies -
Tomography, Optical Coherence -
Treatment Outcome -
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Vitreous Body -

Find related publications in this database (Keywords)
Bevacizumab
Myopic choroidal neovascularization
Pelli-Robson contrast sensitivity
Ranibizumab
© Meduni Graz Impressum